Table 3. Bivariable model of treatment relapse based on baseline characteristics.

Baseline characteristic	Odds Ratio Estimate	95% Confidence Intervals	p-value
RBV Dose: Low dose vs weight-based	2.024	(0.600,6.828)	0.2559
Age: >50yrs vs. ≤ 50yrs	1.777	(0.401,7.880)	0.4491
Genotype: 1a vs. 1b	0.478	(0.125,1.827)	0.2808
Race: Black vs. non black	1.957	(0.348,11.008)	0.4464
Gender: Male vs. Female	6.091	(1.174,31.614)	0.0315
IL28B Genotype: CT/TT vs. CC	1.200	(0.196,7.362)	0.8438
BMI: >30 vs. ≤ 30	0.333	(0.096,1.159)	0.0839
Knodell HAI fibrosis: 3-4 vs. 0-1	4.267	(1.101,16.537)	0.0358
HCV RNA: >800, 000vs. ≤800, 000	5.743	(1.353,24.381)	0.0178

Bivariable analysis of baseline factors showed that in all randomized participants who completed treatment, the odds of relapse was significantly higher in participants who were male, had advanced fibrosis and baseline HCV RNA > 800,000 IU/mL. RBV: ribavirin; BMI: Body mass index;